The safety and anti-cancer effect of radioligand therapy (RLT) with Actinium-225-labeled prostate-specific membrane antigen ( 225Ac-PSMA) in metastatic castration-resistant prostate cancer (mCRPC) patients have been reported in different clinical settings. Despite this, some patients may not respond optimally to 225Ac-PSMA RLT and experience treatment-induced toxicities. It is important to identify the characteristics of patients who may show sub-optimal response to 225Ac-PSMA RLT to guide treatment selection and rationale design of combinatorial therapy approaches. Here, we describe the characteristics and survival duration of mCRPC patients in the WARMTH Act study who did not respond to 225Ac-PSMA RLT.
LAWAL I;
BRUCHERTSEIFER Frank;
BAL Chandrasekhar;
BALLAL Sajana;
CARDACI Giuseppe;
DAVIS Cindy;
EIBER Mathias;
HEKIMSOY Türkay;
KNOESEN Otto;
KRATOCHWIL Clemens;
LENZO Nat P.;
MAHAPANE Johncy;
MASERUMULE Letjie;
MDLOPHANE Amanda;
MOKOALA K;
NDLOVU Honest;
PANT Vineet;
RATHKE H;
REED Janet;
SEN Ishita;
SINGH Aviral;
SOOD Ashwani;
TAUBER R;
THAKRAL Parul;
YADAV Madhav;
MORGENSTERN Alfred;
SATHEKGE Mike;
2024-07-25
SOC NUCLEAR MEDICINE INC
JRC137416
0161-5505 (online),
https://jnm.snmjournals.org/content/65/supplement_2/242591,
https://publications.jrc.ec.europa.eu/repository/handle/JRC137416,
This document is only visible at the Commission level.
You are not authorized to publish or distribute it outside the European Commission.
This is a public document. You can share this publication.
Additional supporting files
| File name | Description | File type | |
|---|
